Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 6;61(10):3930-3938.
doi: 10.1093/rheumatology/keab917.

Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study

Ahmad A Sherbini  1 , James M Gwinnutt  1 , Kimme L Hyrich  1   2 ; RAMS Co-Investigators; Suzanne M M Verstappen  1   2
Collaborators, Affiliations

Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study

Ahmad A Sherbini et al. Rheumatology (Oxford). .

Abstract

Objectives: To estimate prevalence rates and identify baseline predictors of adverse events (AEs) over the first year of treatment in patients with RA starting MTX.

Methods: Data came from the UK Rheumatoid Arthritis Medication Study (RAMS), a prospective cohort of patients with RA starting MTX. This analysis included patients aged ≥18 years with physician diagnosed RA and symptom duration ≤2 years, who were commencing MTX for the first time. AEs were recorded by interviewing patients at 6- and 12-month follow-up visits. The period prevalence rates of AEs are reported for 0-6 months, 6-12 months and 0-12 months of follow-up. The associations between baseline characteristics and AEs were assessed using multivariable logistic regression.

Results: A total of 1069 patients were included in the analysis. Overall, 77.5% experienced at least one AE. The most commonly reported AEs were: gastrointestinal (42.0%), neurological (28.6%), mucocutaneous (26.0%), pulmonary (20.9%), elevated alanine transaminase (18.0%) and haematological AEs (5.6%). Factors associated with increased odds of AEs were: women vs men (gastrointestinal, mucocutaneous, neurological) and alcohol consumption (nausea, alopecia, mucocutaneous). Older age, higher estimated glomerular filtration rate and alcohol consumption were associated with less reporting of haematological AEs.

Conclusions: AEs were common among patients over the first year of MTX, although most were not serious. Knowledge of the rates and factors associated with AE occurrence are valuable when communicating risks prior to commencing MTX. This can help patients make informed decisions whether to start MTX, potentially increasing adherence to treatment.

Keywords: DMARDs; adverse events; methotrexate; prognostic factors; rheumatoid arthritis.

PubMed Disclaimer

References

    1. Smolen JS, Landewe RBM, Bijlsma JWJ. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:685–99. - PubMed
    1. Lopez-Olivo MA, Siddhanamatha HR, Shea B. et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev 2014;CD000957-CD. - PMC - PubMed
    1. Fraenkel L, Bathon JM, England BR. et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheum 2021;73:1108–23. - PubMed
    1. Hope HF, Hyrich KL, Anderson J. et al. The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate. Rheumatology 2020;59:213–23. - PubMed
    1. Hayden C, Neame R, Tarrant C.. Patients’ adherence-related beliefs about methotrexate: a qualitative study of the role of written patient information. BMJ Open 2015;5:e006918. - PMC - PubMed

Publication types